Ankylosing Spondylitis Therapeutics Market to Grow with a CAGR of 7.51% through 2028

Increasing prevalence of Ankylosing Spondylitis Therapeutics and increasing patient advocacy and awareness are factors driving the Global Ankylosing Spondylitis Therapeutics Market in the forecast period 2024-2028.

 

According to TechSci Research report, “Ankylosing Spondylitis Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Ankylosing Spondylitis Therapeutics Market stood at USD 4.41 billion in 2022 and is anticipated to grow with a CAGR of 7.51% in the forecast period, 2024-2028. Ankylosing spondylitis (AS) is a chronic inflammatory condition that primarily affects the spine, leading to pain, stiffness, and reduced mobility. This autoimmune disease affects millions of people worldwide, and the global ankylosing spondylitis market is continually evolving to meet the growing demand for effective treatments and management solutions. Several factors are driving the expansion of this market, from advancements in medical research to changing demographics and increased awareness of the disease.

One of the primary drivers of the global AS market is the increasing prevalence of ankylosing spondylitis. AS is not a rare condition, and its prevalence is on the rise. According to estimates, there are more than 2 million people living with AS in the United States alone, and similar trends are observed worldwide. This surge in the number of AS patients is propelling the demand for better treatment options, creating opportunities for pharmaceutical companies and healthcare providers.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Ankylosing Spondylitis Therapeutics Market.”

 

Recent years have seen significant advancements in the understanding of ankylosing spondylitis at the molecular and genetic levels. Researchers have made substantial progress in unraveling the disease's complex pathophysiology, identifying key biomarkers, and exploring potential therapeutic targets. These scientific breakthroughs are fostering the development of innovative drugs and treatment approaches. As a result, the AS market is witnessing a stream of new, targeted therapies designed to manage the condition more effectively.

Biologic drugs have transformed the landscape of AS treatment. Biologics such as TNF-alpha inhibitors (e.g., Adalimumab, Infliximab) and IL-17 inhibitors (e.g., Secukinumab) have proven highly effective in controlling inflammation and improving patients' quality of life. Their success has fueled research and development efforts, leading to the introduction of new biologics with improved efficacy and safety profiles. The increasing availability of these biologics is a significant driver of the AS market's growth.

Ankylosing spondylitis typically manifests in young adults, but the disease is often lifelong. As the global population ages, a substantial number of individuals are living longer with AS. This demographic shift is resulting in a larger patient pool seeking continuous medical care and treatment, which in turn drives market growth. Healthcare providers and pharmaceutical companies are focusing on addressing the unique needs of older AS patients, further stimulating market expansion.

The growing awareness of ankylosing spondylitis, fueled by patient advocacy groups and awareness campaigns, is another driving force behind the global AS market. These initiatives are helping to reduce the diagnostic delay often associated with AS, leading to earlier intervention and better disease management. As more individuals are diagnosed with AS and seek treatment, the market for AS-related medications, devices, and services continues to expand.

The Global Ankylosing Spondylitis Therapeutics Market is segmented into Drug, End Use and company.

Based on End Use, the hospital segment has emerged as the predominant market leader. Managing AS may require a multi-disciplinary approach involving rheumatologists, physical therapists, and other healthcare professionals. Hospitals are equipped to provide this comprehensive care, including access to advanced diagnostic tools, medication management, and physical therapy. AS is a progressive disease, and regular monitoring is essential to track its progression and adjust treatment plans accordingly. Hospitals offer the necessary infrastructure for conducting regular tests and assessments to monitor patients' health and make informed decisions about their treatment.

Based on region, North America segment is expected to grow during the forecast period. The United States, in particular, is known for its high healthcare spending. This significant investment in healthcare can drive the development and adoption of new AS treatments and therapies, making it a dominant player in the market. The prevalence of AS in North America may also contribute to its dominance in the market. A larger patient population often attracts more attention from pharmaceutical companies and researchers.

The Asia Pacific region is experiencing rapid market growth. The Asia Pacific has active patient advocacy and support groups that raise awareness about AS, support research efforts, and provide resources for patients. These organizations can influence treatment options and market dynamics.

 

Major companies operating in Global Ankylosing Spondylitis Therapeutics Market are:

• AbbVie, Inc.
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• UCB, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.

 

Download Free Sample Report

Customers can also request 10% free customization in this report.

 

“The global ankylosing spondylitis market is poised for significant growth, driven by factors such as increasing prevalence, advances in medical research, the biologics revolution, an aging population, patient advocacy and awareness, and favorable reimbursement policies. These drivers are creating opportunities for pharmaceutical companies, healthcare providers, and other stakeholders to develop and deliver innovative treatments and solutions for AS patients. As research continues and new therapies emerge, the outlook for the global AS market remains promising in its efforts to improve the lives of those affected by this chronic autoimmune condition.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Ankylosing Spondylitis Therapeutics Market By By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia), By End Use  (Hospitals, Clinics, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Ankylosing Spondylitis Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Ankylosing Spondylitis Therapeutics Market.

Contact

Mr. Ken Mathews         

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656                                                     

Email: [email protected]               

Website: www.techsciresearch.com